Out-licensing

We have identified specific apolipoprotein J isoforms whose levels increase up to 100% or decrease up to 50% in the serum of patients with newly acute myocardial infarction, within 6 hours of onset

Up to now there was a lack of early biomarkers for acute myocardial infarction, to allow establishing a diagnosis and thus choosing the best treatment to prevent the worst consequences of this infarction.
Our scientists from CSIC and the Catalan Institute of Cardiovascular Sciences have discovered that in sera from patients with acute myocardial infarction there are modifications in the levels of some isoforms of the apolipoprotein J (Apo J) and that these changes are detectable within 6 hours after the onset of the infarct.
Thus, the levels of some glycosilated isoforms of Apo J show a 2-fold increase and the levels of others are reduce by 50% in sera of patients with acute myocardial infarction, when compared to healthy individuals.
These isoforms are currently being further characterised and antibodies against them are being generated to facilitate the development of a diagnostics test.

Main features and advantages

• Changes in Apo J isoforms are detectable within 6 hours of acute myocardial infarct onset, when the rest of infarction markers, like troponins, do not show any change
  It will allow diagnosing and treating patients sooner, during the early stage of acute myocardial infarct
• The use of specific Apo J isoforms solves the problem of results variability of commercial tests, which quantify only total Apo J. Total Apo J is not a reliable marker there being seemingly contradictory reports of either its increase and decrease in serious coronary conditions
• A clearcut interpretation is now possible: the levels of two isoforms decrease by 50% while those of another three increase by 100%
• The full characterization of isoforms and obtaining antibodies applicable to acute myocardial infarct diagnosis are well advanced

Early Stage

PCT patent application filed

An exclusive patent licence is preferred, but we are open to discuss other approaches

P201030168